Long term headache duration is a factor predicting nonresponse to detoxification and advice in medication overuse headache

Stefano Caproni¹, Elisa Bianchi², Letizia M Cupini³, Ilenia Corbelli¹, Ettore Beghi², Paolo Calabresi¹, Paolo Sarchielli¹* and for SAMOHA Study Group

Abstract

Background: Medication overuse headache (MOH) is a very heterogeneous disorder for which a recommended treatment is not yet available. The purpose of this study was to investigate any possible roles of demographic and clinical characteristics of MOH patients that might predict a response to detoxification and advice with or without preventive treatment.

Findings: This ancillary study is part of the Sodium vAlproate in the treatment of Medication Overuse HeadAche (SAMOHA) study that randomized 88 MOH patients for 3-month treatment period with sodium valproate (VPA) (800 mg/day) or placebo after a 6-day outpatient detoxification regimen. Demographic and clinical characteristics obtained on patients from both study arms were analyzed to point out an association with the response to the treatment. While for patients from VPA arm no significant results were obtained, comparing responders to detoxification and advice to withdraw from MOH, a significant difference in headache duration was observed. Specifically, the efficacy of such treatment resulted ineffective in headache lasting longer than 30 years.

Conclusions: Our findings suggest that the benefit from detoxification and advice can be excluded in MOH of long duration. Therefore, a preventive treatment is suggested particularly for these patients.

Keywords: MOH; Detoxification; Advice; Headache duration; Treatment

Background

Medication-overuse headache (MOH) is a secondary chronic headache having a relevant impact in clinical practice, with a prevalence of 1-2% in the general population [1-3]. MOH is a very heterogeneous disorder for which a recommended treatment is not yet available. The management of MOH currently represents a difficult challenge for clinicians and headache experts [4]. A possible treatment choice is detoxification and the initiation of a prophylactic therapy [5,6]. Nevertheless, the timing of this prophylactic treatment after detoxification remains one of the most debated aspects of MOH care [7] and a matter of concern among patients [8]. In a recent randomized open-label trial, a structured inpatient detoxification program, characterized by the immediate start of a preventive treatment, resulted more effective than advice alone or a structured outpatient program to achieve drug withdrawal [9]. Likewise, the Sodium vAlproate in the treatment of Medication Overuse HeadAche (SAMOHA) study recently showed the efficacy and safety of sodium valproate (VPA), compared to placebo, after detoxification in the short-term treatment of MOH patients with a history of migraine without aura [10]. In light of this, we analyzed data obtained from patients in both arms of the SAMOHA study, in search of demographic and clinical characteristics which could predict a response to detoxification and advice to withdraw from drug abuse.
Table 1 Comparison of demographic and clinical characteristics between responders and non-responders from VPA arm

|                                | Responders (N = 18) | Non-responders (N = 26) | p-value |
|--------------------------------|----------------------|-------------------------|---------|
| **Sex**                        |                      |                         |         |
| F                              | 14 (77.8)            | 21 (80.8)               | 0.8089  |
| M                              | 4 (22.2)             | 5 (19.2)                |         |
| **Age class (years)**          |                      |                         |         |
| 18-34                          | 2 (11.1)             | 3 (11.5)                | 0.8259  |
| 35-44                          | 9 (50)               | 11 (42.3)               |         |
| 45-54                          | 4 (22.2)             | 9 (34.6)                |         |
| 55-64                          | 3 (16.7)             | 3 (11.5)                |         |
| **BMI class**                  |                      |                         |         |
| (<18) underweight              | 0 (0)                | 1 (3.9)                 | 0.4251  |
| (18-24.9) normal weight        | 8 (44.4)             | 16 (61.5)               |         |
| (25-29.9) overweight           | 8 (44.4)             | 6 (23.1)                |         |
| (>30) obese                    | 2 (11.2)             | 3 (11.5)                |         |
| **Comorbidity**                |                      |                         |         |
| No                             | 17 (94.4)            | 20 (76.9)               | 0.1182  |
| Yes                            | 1 (5.6)              | 6 (23.1)                |         |
| **Surgery**                    |                      |                         |         |
| No                             | 2 (11.8)             | 6 (24)                  | 0.3216  |
| Yes                            | 15 (88.2)            | 19 (76)                 |         |
| Missing                        | 1                    | 1                       |         |
| **Headache days/months (V1)**  |                      |                         |         |
| 15-25                          | 12 (66.7)            | 14 (53.8)               | 0.4405  |
| >25                            | 6 (33.3)             | 12 (46.2)               |         |
| **Headache intensity (V1)**    |                      |                         |         |
| Slight                         | 0 (0)                | 1 (3.8)                 | 0.6987  |
| Moderate                       | 6 (33.3)             | 8 (30.8)                |         |
| Severe                         | 12 (66.7)            | 17 (65.4)               |         |
| **Headache days/month (V2)**   |                      |                         |         |
| 15-25                          | 17 (94.4)            | 19 (73.1)               | 0.1216  |
| >25                            | 1 (5.6)              | 7 (26.9)                |         |
| **Headache intensity (V2)**    |                      |                         |         |
| Slight                         | 3 (16.7)             | 3 (11.5)                | 0.7040  |
| Moderate                       | 11 (61.1)            | 19 (73.1)               |         |
| Severe                         | 4 (22.1)             | 4 (15.4)                |         |
| **Headache duration (years)**  |                      |                         |         |
| 0-10                           | 1 (5.6)              | 5 (19.2)                | 0.4249  |
| 11-20                          | 6 (33.3)             | 7 (26.9)                |         |
| 21-30                          | 7 (38.9)             | 6 (23.1)                |         |
| >30                            | 4 (22.2)             | 8 (30.7)                |         |
| **MOH duration (years)**       |                      |                         |         |
| <1                             | 2 (11.1)             | 4 (15.4)                | 0.5182  |
| 1-3                            | 4 (22.2)             | 6 (23.1)                |         |
Methods

Standard protocol approvals, registrations, and patient consents

As an ancillary study, the protocol was submitted for approval to the Ethics Committees of each participating center. The SAMOHA trial was registered on the European Union Drug Regulating Authorities Clinical Trials website (EudraCT code 2007-006773-92; https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006773-92/IT). The SAMOHA study was conducted in accordance with the Declaration of Helsinki and its amendments (Seoul, October 2008). All patients provided their written consent to participate in the study.

Subjects

This is an ancillary study related to the SAMOHA study, a multicenter, randomized, double-blind, placebo-controlled trial. After a 4-week baseline period (during which no study medication was given) 88 MOH patients received a 6-day outpatient detoxification regimen and then a 3-month treatment period using VPA (800 mg/day), followed by a 3-month follow-up (to verify the possibility of a carry-over effect of treatment). After the detoxification phase, patients were advised to discontinue the overused medication. Although acute medications were consented, no specific symptomatic drugs were recommended during follow-up.

The 3-month responder rate (the proportion of patients achieving ≥50% reduction in the number of days with headache per month) was 23.8% for the placebo arm and 45% for the VPA arm, while after the 3-month follow-up period this rate did not differ between the two groups [10].

Statistical analysis

Demographic (sex, age), clinical (body mass index, comorbidity, surgery) and headache characteristics (frequency, intensity, total and MOH duration, overused drugs) in Responders and Non-Responders (R and NR, respectively) from both study arms were compared. Psychiatric comorbidities and personality traits were assessed using the following inventories: Modified MINI-International Neuropsychiatric Interview [11]: 0 vs. 1+ psychiatric disorders; Beck Anxiety Inventory [12]: 0–21 vs. 22+; Beck Depression Inventory [13]: 0–10, 11–20, 21+, Yale Brown Obsessive-Compulsive Scale [14]: 0 vs. 1+; Leeds Dependence Questionnaire [15]: <10, 10–22, >22. All variables were categorized and assessed using the Fisher exact test. Statistical significance was set at the 5% level. Data was analyzed using the SAS package for PC (SAS Institute, Cary, NV; version 9.2).

Findings

For patients in the VPA arm, no differences between R and NR were observed for demographic, clinical and headache characteristics (Table 1). Conversely, for patients in the placebo group, treated by detoxification and advice to withdraw from MOH, a significant difference between R and NR was found only for headache duration, while all the other variables were evenly distributed (Table 2). Specifically, in MOH patients with a history of migraine longer than 30 years, the probability of response to detoxification and advice to withdraw from drug abuse was irrelevant.

With reference to psychiatric comorbidity and personality traits, none of the assessed inventories differed between R and NR (data not shown).

Discussion

To our knowledge, this is one of the few studies analyzing a possible correlation between demographic, clinical and headache characteristics of MOH patients and response to treatment. Our findings suggest that, in presence of a headache lasting more than 30 years, patients seem to have no benefit from detoxification and advice to withdraw from drug abuse, despite the possible placebo effect. Previously, in a cross-sectional epidemiological survey, the severity of dependence scale score could predict successful prognosis related to detoxification in MOH patients without other complicating secondary headaches [16].

| Table 1 Comparison of demographic and clinical characteristics between responders and non-responders from VPA arm (Continued) |
| --- |
| Overused drugs | |
| Analgesics >14d | 9 | 50 | 6 | 23.1 |
| Analgesics combinations >9d | 2 | 11.1 | 3 | 11.5 |
| Drug combinations >9d | 2 | 11.1 | 7 | 26.9 |
| Triptan combinations >9d | 5 | 27.8 | 10 | 38.5 |
| VPA: sodium valproate. |
| BMI: body mass index. |
| V1: baseline first visit. |
| V2: second visit at the start of detoxification. |
| d: days. |
### Table 2 Comparison of demographic and clinical characteristics between responders and non-responders from placebo arm

|                          | Responders (N = 10) | Non-responders (N = 34) | p-value |
|--------------------------|----------------------|-------------------------|---------|
| Sex                      |                      |                         |         |
| F                        | 10 (100%)            | 24 (70.6%)              | 0.0853  |
| M                        | 0 (0%)               | 10 (29.4%)              |         |
| Age class (years)        |                      |                         |         |
| 18-34                    | 4 (40%)              | 4 (11.8%)               | 0.2563  |
| 35-44                    | 2 (20%)              | 12 (35.3%)              |         |
| 45-54                    | 3 (30%)              | 14 (41.2%)              |         |
| 55-64                    | 1 (10%)              | 4 (11.7%)               |         |
| BMI class                |                      |                         |         |
| (<18) underweight        | 0 (0%)               | 2 (6.1%)                | 0.9166  |
| (18–24.9) normal weight  | 6 (60%)              | 21 (63.6%)              |         |
| (25–29.9) overweight     | 3 (30%)              | 6 (18.2%)               |         |
| (>30) obese              | 1 (10%)              | 4 (12.1%)               |         |
| NS                       | 1                    |                         |         |
| Comorbidity              |                      |                         |         |
| No                       | 6 (60%)              | 23 (67.7%)              | 0.7138  |
| Yes                      | 4 (40%)              | 11 (32.3%)              |         |
| Surgery                  |                      |                         |         |
| No                       | 2 (22.2%)            | 15 (44.1%)              | 0.2807  |
| Yes                      | 7 (77.8%)            | 19 (55.9%)              |         |
| Missing                  | 1                    |                         |         |
| Headache days/months (V1)|                      |                         |         |
| 15-25                    | 6 (60%)              | 20 (58.8%)              | 1.000   |
| >25                      | 4 (40%)              | 14 (41.2%)              |         |
| Headache intensity (V1)  |                      |                         |         |
| Slight                   | 1 (10%)              | 1 (2.9%)                | 0.1818  |
| Moderate                 | 2 (20%)              | 16 (47.1%)              |         |
| Severe                   | 7 (70%)              | 17 (50)                 |         |
| Headache days/month (V2) |                      |                         |         |
| <15                      | 0 (0%)               | 2 (5.9%)                | 1.000   |
| 15-25                    | 6 (60%)              | 20 (58.8%)              |         |
| >25                      | 4 (40%)              | 12 (35.3%)              |         |
| Headache intensity (V2)  |                      |                         |         |
| Slight                   | 0 (0%)               | 3 (8.8%)                | 0.2947  |
| Moderate                 | 8 (80%)              | 17 (50)                 |         |
| Severe                   | 2 (20%)              | 14 (41.2%)              |         |
| Headache duration (years)|                      |                         |         |
| 0-10                     | 2 (20%)              | 5 (14.7%)               | 0.0229  |
| 11-20                    | 1 (10%)              | 6 (17.6%)               |         |
| 21-30                    | 7 (70%)              | 9 (26.5%)               |         |
| >30                      | 0 (0%)               | 14 (41.2%)              |         |
The challenge of achieving a stable withdrawal from medication overuse is one of the most disputed aspects in the treatment of MOH. This lack of agreement is, for the most part, due to the heterogeneity of patients, over-used medications, detoxification procedures and protocol designs [17].

Detoxification is often the first step in withdrawal from medication overuse. In this regard, some studies have suggested benefits from detoxification followed by advice for MOH [9]. Other studies have supported the efficacy of simple advice as a withdrawal strategy in MOH [18,19]. However, in most of these studies there were no controls nor comparisons between responders and non-responders.

The results from our study suggest that in MOH patients with a history of headache longer than 30 years, even in the absence of relevant comorbidities, there is no benefit from detoxification and advice without preventive therapy. This lack of benefit could be due to the lingering central sensitization underlying the pathophysiology of MOH [17]. In these cases, we would suggest an immediate initiation of a prophylactic treatment, to avoid a relapse of drug abuse. This therapeutic approach could lead to a swifter clinical response, better quality of life and economic savings. It is also interesting that MOH duration did not differ in R and NR; this aspect should be further investigated, in order to hypothesize common or different pathophysiological mechanisms for migraine and MOH.

Our study has some limitations. First, the available sample size is incompatible with definitive results regarding the demographic and clinical characteristics we investigated. Given the small numbers, we could not perform a multivariate analysis of our data. So, headache duration may be masked by other confounding variables. Second, some of the patients in our study were included in the placebo arm of the SAMOHA study and, as such, they did not know if they were untreated. Even if a placebo effect cannot be ignored in MOH patients, the validity of our research hypothesis is weakened but not entirely excluded. Third, as our study analyzed the short-term efficacy of treatment, the long-term response to detoxification and advise is unknown.

In conclusion, in the case of headache of long duration our findings suggest that the benefit from detoxification and advice can be excluded in MOH patients. Therefore, a preventive treatment is suggested for these patients. Larger studies with longer follow-up are needed on this issue as their results could lead to a better management of MOH patients.

Abbreviations
MOH: Medication-overuse headache; SAMOHA: Sodium vAlproate in the treatment of Medication Overuse HeadAche; VPA: Sodium valproate; R: Responders; NR: Non-responders.

Competing interests
Dr. Caproni, Dr. Bianchi, Dr. Cupini, Dr. Corbelli, Dr. Sarchielli report no disclosures; Dr. Beghi reports personal fees from Viropharma for participation in a Steering Committee, personal fees from GSK for a seminar in a teaching course, grants from the Italian Drug Agency (AIFA), the Italian Ministry of Health, the American ALS Association, and from Eisai and UCB-Pharma; outside the submitted work; Prof. Calabresi has received research grants from: Bayer, Schering, Biogen, Boehringer Ingelheim, Eisai, Novartis, Lundbeck, Merck Sharp & Dohme, Sanofi-Aventis, Sigma-Tau, and UCB Pharma.

Authors’ contributions
SC contributed in drafting/revising the manuscript, study concept and design, analysis and interpretation of data, acquisition of data, statistical analysis, study supervision or coordination and obtaining funding. EB contributed in drafting/revising the manuscript, analysis and interpretation of data and statistical analysis. V1: baseline first visit. V2: second visit at the start of detoxification. d: days. MOH duration (years)

| MOH duration (years) | 1 | 10 | 5 | 14.7 | 0.9159 |
|----------------------|---|----|---|------|-------|
| <1                   | 3 | 30 | 12 | 35.3 | 0.7442 |
| 1-3                  | 2 | 20 | 5  | 14.7 | 0.7442 |
| 3-5                  | 4 | 40 | 9  | 26.5 |
| >5                   | 1 | 10 | 8  | 23.5 |

BMI: body mass index. V1: baseline first visit. V2: second visit at the start of detoxification. d: days.

| Overused drugs       | MOH duration (years) | MOH duration (years) |
|----------------------|----------------------|----------------------|
| Analgesics >14d      | 3                    | 30                   |
| Analgesics combinations >9d | 2             | 20                   |
| Drug combinations >9d | 4                    | 40                   |
| Triptan combinations >9d | 1            | 10                   |

Table 2 Comparison of demographic and clinical characteristics between responders and non-responders from placebo arm (Continued)
Long term headache duration is a factor

Acknowledgements

SAMOHA Study Group: Elisabetta Pupillo, PhD (Istituto di Ricerche Farmacologiche "Mario Negri", Milano, Italy); L.A. Pinti, MD (Centro Cefalea, Università degli Studi di Modena e Reggio Emilia, Reggio Emilia, Italy); Cesare Iani, MD (Centro Cefalea e Malattie Cerebrovascolari, Ospedale S. Eugenio, Roma, Italy); P. Livrea, MD and Maria Pia Prudenzano, MD (Clinica Neurologica, Policlinico di Bari, Italy); G. Bernardi, MD and Marina Diommede, MD (Clinica Neurologica, Policlinico Tor Vergata, Roma, Italy); G. Tedeschi MD and Antonio Russo, MD (Clinica Neurologica, II Università degli Studi di Napoli, Italy); F. Pitsani, MD and Laura Rosa Pisani, MD (Clinica Neurologica, Università di Messina, Italy); G. Bono, MD and Giulia Misaggi, MD (Centro Cefalea/Sez. UCADH - Università degli Studi dell’Insubria, Varese, Italy); V. Di Piero, MD and Laura Di Clemente, MD (Dipartimento di Neurologia e Piaciutti “Sapienza” Università di Roma, Italy); G. Sandrini, MD and Marta Allena, MD (IRCCS Fondazione “Istituto Mondino”, Università di Pavia, Italy). Dr. Sarchielli confirms that obtained written permission from each co-investigator.

Funding

This project proposal was approved and funded (announcement year 2006) by “Agenzia Italiana del Farmaco” as part of the project AREA “Pharmacoepidemiological studies aimed at defining the benefit-risk profile of treatments and the impact of strategies for improving the appropriateness of drug use. TOPIC: Studies on pharmacological treatments of chronic headache”. Dr. Sarchielli had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Author details

1Clinica Neurologica, Azienda Ospedaliera, Università di Perugia, Sant’Andrea delle Fratte, 06156 Perugia, Italy; 2IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Via La Masa, 19-20156 Milano Milano, Italy; 3 Centro Cefalea e Malattie Cerebrovascolari, Ospedale S. Eugenio, Piazzale dell’Umanesimo, 10 00144 Roma, Italy; 4IRCCS Fondazione “S. Lucia”, Via Ardeatina, 306, 00142 Roma, Italy.

Received: 10 October 2014 Accepted: 6 December 2014
Published: 15 December 2014

References

1. Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808

2. Colás R, Muñoz P, Temprano R, Gómez C, Pascual J (2011) Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology 62:1338–1342

3. Calabresi P, Cupini LM (2005) Medication-overuse headache: similarities with drug addiction. Trends Pharmacol Sci 26:62–68

4. Paemeleire K, Crevits L, Goadozby PJ, Kaulbe H (2006) Practical management of medication-overuse headache. Acta Neurol Belg 106:43–51

5. Olesen J (2012) Detoxification for medication overuse headache is the primary task. Cephalalgia 32:420–422

6. Corbelli I, Caproni S, Eusebi P, Sarchielli P (2012) Drug-dependence behaviour and outcome of medication-overuse headache after treatment. J Headache Pain 13:653–660

7. Zeeberg P, Olesen J, Jensen R (2006) Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 26:1192–1198

8. Munksgaard SB, Allena M, Tasorelli C, Rossi P, Katsarava Z, Bendtsen L, Nappi G, Jensen R, Conocesus Consortium (2011) What do the patients with medication overuse headache expect from treatment and what are the preferred sources of information? J Headache Pain 12:91–96

9. Rossi P, Faroni JV, Tasorelli C, Nappi G (2013) Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial. J Headache Pain 14:10

10. Sarchielli P, Messina P, Cupini LM, Tedeschi G, Di Piero V, Livrea P, Pini LA, Bernardi G, Bono G, Sandrini G, Caproni S, Corbelli I, Pisanì F, Begeh E, Galabreis P (2014) Sodium valproate in migraine without aura and medication overuse headache: A randomized controlled trial. Eur Neuropsychopharmacol 24:1289–97

11. Aronson P, Lecrubier Y, Weller E, Herguet A, Sheehan D (1998) DSM-IV-R Psychotic Disorders: procedural validity of the Min International Neuropsychiatric Interview (MINI). Concordance and causes for discordance with the CIDI. Eur Psychiatry 13:26–34

12. Osman A, Kopper BA, Barrios FX, Osman JR, Wade T (1997) The Beck anxiety inventory: reexamination of factor structure and psychometric properties. J Clin Psychol 53:7–14

13. Richter P, Weinier J, Heekel A, Kraus A, Sauer H (1998) On the validity of the Beck depression inventory. A review. Psychopathology 31:160–168

14. Kim SW, Dysken MW, Kuskowski M (1990) The Yale-Brown obsessive-compulsive scale: a reliability and validity study. Psychiatry Res 3499–106

15. Raatik M, Braddow J, Toder G, Weiner J, Allison J, Healey C (1994) Development of the Leeds Dependence Questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction 89:563–572

16. Lundqvist C, Grande RB, Asseh K, Russell MB (2012) Dependence scores predict prognosis of medication overuse headache: a prospective cohort from the Akershus study of chronic headache. Pain 153:682–686

17. Kristoffersen ES, Lundqvist C (2014) Medication-overuse headache: a review. J Pain Res 7:367–378

18. Rossi P, Faroni JV, Nappi G (2011) Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol 18:396–401

19. Grande RB, Asseh K, Bernt JØ, Lundqvist C, Russell MB (2011) Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. Eur J Neurol 18:129–137

doi:10.1186/1129-2377-15-88

Cite this article as: Caproni et al: Long term headache duration is a factor predicting nonresponse to detoxification and advice in medication overuse headache. The Journal of Headache and Pain 2014 15:88.

Submit your next manuscript at ➤ springeropen.com

Submit your manuscript to a SpringerOpen journal and benefit from:

➤ Convenient online submission
➤ Rigorous peer review
➤ Immediate publication on acceptance
➤ Open access: articles freely available online
➤ High visibility within the field
➤ Retaining the copyright to your article